Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.
about
Micro-CT Imaging Reveals Mekk3 Heterozygosity Prevents Cerebral Cavernous Malformations in Ccm2-Deficient MiceDietary Vitamin D and Its Metabolites Non-Genomically Stabilize the EndotheliumKLF4 is a key determinant in the development and progression of cerebral cavernous malformations.Combined HMG-COA reductase and prenylation inhibition in treatment of CCM.The pathobiology of vascular malformations: insights from human and model organism genetics.Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes.Vascular permeability in cerebral cavernous malformations.Defective autophagy is a key feature of cerebral cavernous malformations.Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1.Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine.Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease.Up-regulation of NADPH oxidase-mediated redox signaling contributes to the loss of barrier function in KRIT1 deficient endothelium.Beyond multiple mechanisms and a unique drug: Defective autophagy as pivotal player in cerebral cavernous malformation pathogenesis and implications for targeted therapies.Vitamin D administration during pregnancy as prevention for pregnancy, neonatal and postnatal complications.Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin.The molecular basis of endothelial cell plasticity.Identification of Potential Therapeutics to Conquer Drug Resistance in Salmonella typhimurium: Drug Repurposing Strategy.High-Throughput Imaging for the Discovery of Cellular Mechanisms of Disease.Application of Imaging-Based Assays in Microplate Formats for High-Content Screening.Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease.New insights into the vitamin D requirements during pregnancy.Platinum nanozymes recover cellular ROS homeostasis in an oxidative stress-mediated disease model.KRIT1 loss-of-function induces a chronic Nrf2-mediated adaptive homeostasis that sensitizes cells to oxidative stress: Implication for Cerebral Cavernous Malformation disease.Calcium influx through TRPV4 channels modulates the adherens contacts between retinal microvascular endothelial cells.Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model.Drug repurposing: An approach to tackle drug resistance in S. typhimurium.RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.Dysregulated exocytosis of angiopoietin-2 drives cerebral cavernous malformation.CellProfiler 3.0: Next-generation image processing for biologyMachine learning and image-based profiling in drug discoveryBiological Activities, Health Benefits, and Therapeutic Properties of Avenanthramides: From Skin Protection to Prevention and Treatment of Cerebrovascular DiseasesSystematic pharmacological screens uncover novel pathways involved in cerebral cavernous malformations
P2860
Q27329910-4BA1BED1-451C-49AE-92CE-87F810D73354Q28550290-AE23B15B-CB95-49FD-A4B3-703C406D0F0EQ30278010-B5F0A324-804A-44E9-95F5-53264CC5C318Q33737847-B5F413C7-1C64-4425-86FF-C84F8F4A3665Q34544980-A855B17A-CA8B-4096-8727-0CEA5D01170CQ36112726-B9B54A0C-634C-46ED-A669-5B1D50759AB0Q36267403-24DE1DCE-A726-43C3-8779-F25CB3849177Q36278717-5E5C7E8F-3DD4-4F51-800F-718D3346ACE7Q36641687-0F0A932B-0A58-4A62-841F-6AF6F7F31553Q36892606-0A3738E7-3C77-4E86-9955-E4B1A6D96BA2Q37029832-16875DEA-E88F-437B-A897-8FE0FC5EF961Q37050968-241DDD5F-BBB6-4CA7-A67A-F27FAC8C1580Q38622980-7D9DACB2-D28C-423C-8EFD-10A3163FA494Q38824364-22038C69-A2CD-472D-AB1E-352C05F27F9CQ38953734-346F8657-2E07-4B44-8F70-834B3435B271Q38957623-2D047009-CCDD-4FAF-BB5F-22378AA5A3FBQ39127982-A8E2D871-E6A5-40AE-87DD-1C2B92288BB7Q39268520-AE5271AC-E346-41A9-9DFF-E691E2985560Q39451018-F71E7668-019B-456A-B884-E20D97A1BE3EQ39674242-1469D6B9-6CA0-470E-AF39-1ADEB2EEDB9CQ40968561-D6B41F4D-5FD5-471A-BD94-3AAFB4382E27Q41540480-2CB990FF-6260-46FE-8EF0-E219B0C28C4FQ46604327-579876B9-E27F-4F53-8D16-BB0DD90CE924Q47369895-12A33473-844F-4D90-868E-02F1103DB314Q47742566-735E0F21-8AAC-43DA-A5DA-3C9599FA41CBQ48118976-9605A793-5ADF-49AD-947F-E114E974A475Q48146177-A22AC818-7C9C-4B20-8572-693376A02A5FQ48419319-2621307A-06BB-45A0-BA01-C1214DC7B1B5Q48526422-50DBBA36-D798-44D8-96CC-0A6EF94D9464Q56395621-E750B30F-FA3F-4049-A90F-BF2E87A82E7FQ57171910-035FD24F-198F-4315-8AA0-443F27A7B298Q58711702-DD881EA9-22BE-4222-BE96-078DC68D8195Q58764066-E1DBFFA8-1A18-4C6D-BBB6-8F1EEA3755DD
P2860
Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Strategy for identifying repur ...... rebral cavernous malformation.
@ast
Strategy for identifying repur ...... rebral cavernous malformation.
@en
type
label
Strategy for identifying repur ...... rebral cavernous malformation.
@ast
Strategy for identifying repur ...... rebral cavernous malformation.
@en
prefLabel
Strategy for identifying repur ...... rebral cavernous malformation.
@ast
Strategy for identifying repur ...... rebral cavernous malformation.
@en
P2093
P2860
P50
P1433
P1476
Strategy for identifying repur ...... erebral cavernous malformation
@en
P2093
Allie H Grossmann
Anthony J Donato
Chadwick T Davis
Christopher C Gibson
Jay A Bowman-Kirigin
Kevin J Whitehead
Kirk R Thomas
Lisa A Lesniewski
P2860
P304
P356
10.1161/CIRCULATIONAHA.114.010403
P407
P577
2014-12-08T00:00:00Z